UCLA's Jonsson Comprehensive Cancer Center : JCCC Member Directory

Mitchell Kamrava, M.D.

Specialty:

Radiation Oncology

General Information:

Gender:	Male
Language(s):	English, Farsi, Spanish

Affiliation(s):

Assistant Clinical Professor, Department of Radiation Oncology

Member, JCCC Cancer Molecular Imaging Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Santa Monica-UCLA Medical Center and Orthopaedic Hospital

Education:

Fellowship:	Brachytherapy, UCLA School of Medicine, 2010 - 2011
Residency:	Radiation Oncology, National Cancer Institute, 2006 - 2010
Internship:	Internal Medicine, Stanford University Medical Center, 2005 - 2006
Medical Degree:	M.D., UCSD School of Medicine, 2005

Certification(s):

Medical Board Certification(s):	Radiation Oncology, American Board of Radiology, 2011

Contact Information:

Phone:	(310) 825-9775
Email:	mkamrava@mednet.ucla.edu
Website:	http://radonc.ucla.edu/body.cfm?id=216

Practice Information:

Clinical Interest(s):	Gynecologic malignancies General brachytherapy

Scientific Interest(s):

Dr. Mitchell Kamrava is interested in incorporating multiparametric MRI into radiation treatment planning and investigating its role as a predictive/prognostic imaging marker. He is also active in the validation of serum and urine biomarkers for patients receiving radiation.

Selected Cancer-Related Publications:

Gulley JL, Madan RA, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, Kamrava M, Schlom J, Citrin D. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin Biol Ther. 2011 Nov;11(11):1409-18. Epub 2011 Aug 28.

Wuthrick EJ, Kamrava M, Curran WJ Jr, Werner-Wasik M, Camphausen KA, Hyslop T, Axelrod R, Andrews DW, Glass J, Machtay M, Dicker AP. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. Cancer. 2011 Jun 3. doi: 10.1002/cncr.26216. [Epub ahead of print]

Kamrava M, Gius D, Casagrande G, Kohn E. Will targeting insulin growth factor help us or hurt us?: An oncologist's perspective. Ageing Res Rev. 2011 Jan;10(1):62-70. Epub 2009 Nov 5.

Kamrava M, Bernstein MB, Camphausen K, Hodge JW. Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination? Mol Biosyst. 2009 Nov;5(11):1262-70. Epub 2009 Aug 27.

Kamrava M, Tsang KY, Madan RA, Kaushal A, Coleman CN, Gulley J. Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer. Clin Dev Immunol. 2009;2009:363914. Epub 2010 Mar 8.